Vanda Pharmaceuticals Inc has a consensus price target of $12.5 based on the ratings of 2 analysts. The high is $13 issued by Cantor Fitzgerald on August 1, 2024. The low is $12 issued by Jefferies on February 25, 2022. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Cantor Fitzgerald, and Jefferies on August 1, 2024, July 11, 2024, and February 25, 2022, respectively. With an average price target of $12 between Cantor Fitzgerald, Cantor Fitzgerald, and Jefferies, there's an implied 151.57% upside for Vanda Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Vanda Pharma (NASDAQ:VNDA) was reported by Cantor Fitzgerald on August 1, 2024. The analyst firm set a price target for $13.00 expecting VNDA to rise to within 12 months (a possible 172.54% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Vanda Pharma (NASDAQ:VNDA) was provided by Cantor Fitzgerald, and Vanda Pharma maintained their overweight rating.
There is no last upgrade for Vanda Pharma
The last downgrade for Vanda Pharmaceuticals Inc happened on February 25, 2022 when Jefferies changed their price target from $24 to $12 for Vanda Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vanda Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vanda Pharma was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.
While ratings are subjective and will change, the latest Vanda Pharma (VNDA) rating was a maintained with a price target of $11.00 to $13.00. The current price Vanda Pharma (VNDA) is trading at is $4.77, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.